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1. Introduction
Coronary artery disease is the single leading cause of death in the United States. Every year
more than 1 million open coronary revascularization procedures are performed in the United
States. Most commonly the greater saphenous veins and internal mammary and/or radial
arteries are used as bypass conduits. Long term patency and avoiding repeat revascularization
is every surgeon’s goal following coronary artery bypass grafting. Unfortunately it is estimated
that during the first year after surgery; between 10 - 15% of venous grafts occlude. The graft
attrition rate is estimated to be 1 - 2 % per year during the first five years following surgery.
By 10 years only 50 % of vein grafts remain free from significant stenosis [1].
The reasons for premature graft closure include; biologic, conduit quality, unsatisfactory
harvest/preparation, and inappropriate operative strategy or poor surgical technique [2].
Many of these factors can be avoided with proper technique and experience of the surgical
team. Currently much of the research being performed on graft failure is leading to the
hypothesis of early thrombosis and neointimal hyperplasia as the physiologic basis for graft
failure, although the exact mechanism is not well established.
This chapter will discuss current knowledge and ongoing research regarding the thrombosis,
intimal hyperplasia and atherosclerosis of vein grafts. It will highlight harvesting techniques
and preservation methods, as well as discuss proposed mechanisms that lead to intimal
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hyperplasia, graft atherosclerosis, and the evolving strategies and current research for long-
term prevention of graft failure.
2. How vein harvesting methods can affect patency rates
Dr. Rene Favaloro developed the first saphenous vein harvesting technique in 1967 [2]. This
technique required a longitudinal incision along the length of the greater saphenous vein
entering the fascial canal surrounding the vein and thus causing inadvertent damage to the
adventitial layer. Following vein isolation from the surrounding tissues, ligation of side
branches, as well as a transection of the vein for completion of the harvest is performed. Since
that original description, many methods have evolved from Dr. Favaloro’s original technique.
As well, research has focused on the best method of harvesting grafts without damage. In
addition to Favaloro’s original technique, current and popular harvesting techniques included;
“no touch”, stab phlebectomy, and most recently endoscopic techniques. It is inherit that
manipulation of the vein conduit causes damage to the vein itself, but the extent was unknown.
Multiple studies have been done to compare; “open”, “no touch”, and “endoscopic vessel
harvesting (EVH)” techniques [3]. The traditional open technique which is performed under
direct visualization of the vein was found to preserve the endothelium of the vein quite well,
but also came with the complications of leg pain i.e. wound healing, post operative cellulitis,
and increased length of hospital stay [4], [5]. Initial studies performed on the long-term
outcome of vein grafts harvested using the open technique did show that the vein was often
stripped of the beneficial adventitial layer as well as distended to high pressures to overcome
the associated vasospasm [6]. Unfortunately, the increased distention pressures caused shear
stress damage to the vein intima and subsequent endothelial wall [7]. When viewed histolog‐
ically the endothelial cells appeared deformed, flattened, polymorphic, and contained an
abundance of cytoplasmic vesicles [8]. As a method to avoid over-handling of the vein and
increased distention pressures a pedicle technique was developed and named the “no touch”
technique. It was thought that veins procured in this manner would eliminate the need for
conduit distention and its associated morbidities since the perivascular adipose tissue
surrounding the vein was left intact [9]. It had been shown that this surrounding tissue in
internal thoracic mammary arteries provided a vasodilatory effect with less arterial conduit
vasospasm. Increased patency rates were demonstrated with the “no touch” technique
compared to the conventional open technique [9]. 1997 began a new era in coronary artery
bypass grafting with the use of EVH to harvest the saphenous vein. Endoscopic harvesting
techniques were found to eliminate the need for invasive incisions, and decrease the associated
risks that accrued with an open technique. Furthermore veins harvested via an EVH method
were hypothesized to be promising for graft patency, since endothelial integrity was main‐
tained following EVH harvest compared to other conventional harvesting techniques. This
new technique soon became the standard of care with greater than 70% of saphenous vein
conduits being retrieved in this manner [10]. Endoscopic harvesting had lower complication
rates including less post-operative pain, and decreased patient length of stay. However,
controversy arose about the long-term patency of the vein conduits after coronary artery
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bypass grafting; depending upon what vein harvest method was used in surgery. It was felt
veins harvested using an EVH technique failed more often and earlier than veins harvested in
the traditional open technique. Studies performed by Desai et al in 2011, confirmed the
relationship between the learning curve of EVH and the patency rates based on beginner and
expert level of experience in harvesting vein tissue [11]. It has since been shown that when a
novice is performing the procedure the vein is subjected to much more stress from trying to
better visualize the vein, and 50% of the veins had discrete areas of injury [11]. It was noted
that if a section of vein had more than 4 areas of injury, it had a greater than 50% risk of failure
of patency [11]. Early studies, which compared the traditional open harvest method to EVH,
were published in the infancy stages of EVH when all harvesters were novices to this new
technique. Thus, it is now recognized that this confounding issue may have contributed to the
decreased long-term patency that was noted. However, this has changed in the past years with
“novice” level practitioners becoming experts. It has recently been found that when procured
by expert level harvesters the physical damage to the vein is similar to that of open harvest [12],
[13]. Thus, it is hypothesized that EVH and open harvest when performed by an expert will
have similar patency rates if all other factors are equal.
3. The role of pressure distention and wall stress during harvest
Standard procedure in the United States is to distend the saphenous vein graft after procure‐
ment prior to myocardial implantation to ensure that all branches are ligated. The majority of
the time during harvest, the vein is distended to supra-physiologic pressures [14]. While
saphenous veins in vivo are rarely subjected to pressures greater than 60 mmHg, recorded
pressure measurements during harvest easily reach 300-400 mmHg [15]. This supra-physio‐
logic pressure severely damages the endothelium and ultimately leads to premature graft
closure. This high pressure is inadvertently used to overcome vasospasm as well as to ensure
ligation of all side branches [16]. The pressure causes shear wall stress that denudes the
protective endothelial layer (Figure 1). As a mechanism to protect itself, the endothelium
releases basic fibroblast growth factors and platelet-derived growth factors [17]. Basic fibro‐
blast growth factor, a heparin-binding polypeptide that is present in the nucleus and cytoplasm
of smooth muscle and endothelial cells and in the intracellular matrix, is normally a non-
secreted cell product [18]. Platelet derived growth factor is also widely acknowledged in the
process of angiogenesis and most specifically in cell migration and proliferation. The release
of these 2 mitogens together initiates intimal hyperplasia [17].
4. The graft “environment” at a cellular level
The vascular endothelium has many protective functions, and it releases factors that maintain
vein graft patency. The endothelium serves as the physical barrier between the blood compo‐
nents and the sub-endothelium, damage to this endothelium by either direct or indirect stress
can disrupt this protective environment causing the formation of atheromas and subsequently
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graft failure. Injury to the endothelium in addition to surgical manipulation also increases the
risk for vasospasm, stenosis, and intimal hyperplasia. Studies have shown that many factors
can affect the viability of endothelium; these include temperature, distention, and the compo‐
sition of solution used in vein preparation. Nitric oxide controls vascular tone in addition to
causing vasodilatation. Vascular endothelium contains L-arginine which when combined with
nitric oxide synthase forms nitric oxide1. The main target of nitric oxide is to stimulate
guanylate cyclase and subsequently form guanosine 3 prime 5 prime-cyclic monophosphate
(cGMP). The cGMP leads to vasodilatation and inhibition of platelet aggregation [19]. Fur‐
thermore, nitric oxide also has been shown to interfere with cell migration, specifically white
cells by reducing the adhesion of neutrophils to the endothelial surface. Several cytoprotective
properties are conferred through nitric oxide including; scavenging of oxygen free radicals
and blocking release of prostaglandin E2 and F2 alpha. These are anti-inflammatory effects,
and are quite intricate in detail, but are based on regulation of transcription factors [20], [21].
Nitric oxide also has some cytotoxic effects including decreasing protein synthesis, increasing
lipid peroxidation, and decreasing acute phase proteins [22]. Injury to the endothelium directly
causes a decrease in nitric oxide release by the endothelial cells and destroys the integrity of
the vein. Studies performed by Kown et al. showed that vein grafts treated with L-arginine
(nitric oxide is a by-product created when L-arginine is converted to citrulline) can increase
levels of nitric oxide and subsequently decrease hyperplasia [23].
5. Reperfusion injury
Approximately 12% of patients experience thrombosis of saphenous vein grafts within 30 days
of surgery [24]. It has been shown that this acute thrombosis is likely a combination of multiple
factors including ischemia and hemostasis during coronary procedures which favors throm‐
bogenesis [25]. The ischemic period in which the vein has been harvested but not yet re-
implanted into the myocardium, marks the beginning of the cascade to possible thrombosis.
Upon re-establishment of blood flow through the vein it has been shown that neutrophils in
the oxygenated blood are attracted to the areas of endothelial injury [26]. This ischemia-
reperfusion results in a reduction in both basal and stimulated nitric oxide release, yet
attenuates the vaso-relaxation responses to the agonist stimulators of endothelial nitric oxide
acetylcholine and bradykinin. Together this impairs the release of nitric oxide and down
regulates nitric oxide production after an ischemic event.
After the saphenous vein is harvested, the initial injury causes a decrease in nitric oxide due
to the traumatic endothelial cell injury from manipulation and distention. Following the
ischemic period and after implantation, nitric oxide synthesis will increase due to the reper‐
fusion. Re-implantation causes release of multiple growth factors, and cytokines that cause the
migration and proliferation of vascular smooth muscle cells and formation of extracellular
matrix into the intimal compartment of the vein graft. Once neutrophils are adherent they
initiate further endothelial damage and activation of the coagulation cascade which can lead
to thrombosis [1]. The release of nitric oxide at this time can limit neointimal hyperplasia by
inhibiting this proliferation and promoting apoptosis [27].
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6. The role of neointimal hyperplasia in graft patency
Neointimal hyperplasia is the accumulation of smooth muscle cells and extracellular matrix
that occurs in the intimal layer of vein. This thickening leads to a narrowing of the lumen
and  subsequent  stenosis  of  the  vein  graft.  Neointimal  hyperplasia  is  the  most  widely
accepted reason for graft  failure at  the present time. Many theories exist  as to why this
occurs  but  none  have  been  completely  proven.  Work  is  currently  being  performed
evaluating the up regulation of genes or proteins that may cause the phenomenon of intimal
hyperplasia [15]. Nearly all vein grafts placed into an arterial system develop some areas
of hyperplasia within the first four weeks. This acute hyperplasia can narrow the lumen
of the vein conduit by as much as 25%.
Many studies have related extensive endothelial injury to neointimal hyperplasia develop‐
ment. Injury can be in the form of extreme venous distention, denudation of the endothelium
itself, and degree of vasospasm overcome during harvest [28]. Intimal growth is stimulated
by several factors including platelet derived growth factor, transforming growth factor beta,
and epidermal growth factor which cause proliferation and subsequent invasion of the smooth
muscle cells into the intimal layer [1]. When veins are injured, basic fibroblast growth factor
is released from the endothelial cells and smooth muscle cells. This is a very potent mitogen
that causes the increased production of multiple regulatory proteins, kinases, and genes that
participate in DNA synthesis [29]. The sequential activation and inactivation of the cyclin
dependent regulatory kinases (Cdk) leads the smooth muscle cells through the cell cycle [30].
Each cyclin exhibits a cell cycle phase specific pattern of expression with several cell cycle
checkpoints at the G1/S station. At these points the kinases interact with a cyclin, specifically
D and E interacting with Cdk 4/6, and 2. To progress the cell into the M phase cyclin B is
activated. These Cdk proteins are inhibited by activating Cdk 1. The G1 Cdk is part of the
retinoblastoma pocket proteins that when phosphorylated can sequester cell cycle regulatory
transcription factors. This phosphorylation by retinoblastoma proteins as well as specific cylcin
dependent kinases during late G1 leads to activation and release of genes that participate in
DNA synthesis. It is this complex cascade of cellular activities that leads to proliferation of
smooth muscle cells causing neointimal hyperplasia1, [30]. Further research has shown that
other theories also exist as to the mechanism of neointimal hyperplasia that includes a role for
perivascular fibroblasts and matrix metalloproteinases (MMP’s). It is thought that fibroblasts
invade through the media of the saphenous vein graft and differentiate into myofibroblasts.
MMP’s are the mediators of matrix deposition and degradation, which can cause neointimal
hyperplasia. Theories exist that a strategy to avoid hyperplasia would be to use MMP inhibi‐
tors. MMPs compose a super family of 66 known zinc peptidases that degrade collagen, gelatin,
and elastin31. MMPs are critical for cell growth and proliferation, cell migration, organ
development, reproduction, and tissue remodeling. In all of these biological phenomena,
matrix degradation is needed to facilitate changes in cell phenotype. For example, ligand-
dependent cell-matrix associations are critical for modulating cell function, and matrix
degradation. These interactions can thereby modulate responses of the cell to its microenvir‐
onment within the saphenous vein.
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Vascular smooth muscle cells, monocytes/macrophages, and endothelial cells have all been
shown to express MMPs. Vein graft stenosis appears to be associated with increased expression
of MMP-9 and increased activation of MMP-2 [32]. Pharmacological inhibitor studies demon‐
strate that MMPs are, indeed, involved in the formation of the neointima. Therefore, with this
data it appears that MMPs are critical for smooth muscle cell migration and proliferation,
which serve as the cellular basis for neointimal proliferation in vivo. Tissue inhibitors of
metalloprotienases (TIMPs) are four naturally occurring proteins that inactive MMP’s by
binding to them. Kranzhofer et al showed that three of these TIMPs are found on saphenous
vein grafts [33]. Several regulatory mechanisms exist to keep a precise balance between
enzymes that degrade matrix and proteins that inhibit their action. Cytokines and growth
factors, specifically platelet derived growth factor BB act together through a protein kinase C
dependent mechanism to increase the expression of MMP-9, whereas transforming growth
factor-beta and platelet derived growth factor BB induce TIMP-3 expression in vascular smooth
muscle cells [31]. However, they do not have any influence on TIMP-1, or TIMP-2 expression.
Baker et al. transfected grafts with a gene for TIMP-3 and observed an 84% reduction in
neointima at 14 days and 58% reduction at 28 days in porcine vein grafts [34]. This shows
promise for a potential preventative treatment of neointimal hyperplasia, but problems such
as weakening of pre-existing atherosclerotic plaques need to be addressed and the longer-term
benefits of this therapy remain unknown.
7. Upregulation of innate inflammatory markers and graft failure
Studies have shown that patients who present with unstable angina after revascularization by
previous bypass procedures do so because of an obstructive atherosclerotic lesion in the
saphenous vein conduit, and graft stenosis. These plaques have been seen as early as 1 year
after bypass procedures [35]. When the vein conduit plaque is viewed histologically, it is found
to have an increased number of foam cells than in arterial atheromatous plaques. Recent studies
support the theory that a stimulus must exist that induces the expression of inflammatory
mediators and may be the inciting factor leading to intimal hyperplasia and eventual graft
failure [15].
Scavenger receptor proteins play a vital early role in vascular inflammation. Scavenger
receptor proteins on the surface of vascular endothelial cells and macrophage have been shown
to upregulate NF-kappaB inflammatory pathways. Studies focusing on upregulation of
inflammatory markers following distention compared to non distended vein segments have
shown that expression of scavenger receptor-A, scavenger receptor- B, and CD36 are upregu‐
lated in the distended saphenous vein tissue [15]. This suggests that the process of distention
is an inciting event that allows for the upregulation of scavenger receptors, leading to graft
failure through atherosclerotic lesion progression initiated by the formation of foam cells in
these saphenous vein grafts.
Pressure distention of saphenous vein conduits has been part of the standard vein preparation
procedure for decades. The longer the vein is exposed to pressure distention the higher the
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expression of biomarkers. These biomarkers include; toll like receptors (TLRs), intracellular
adhesion molecules (ICAM), vascular cell adhesion molecule-1 (VCAM-1), and platelet
endothelial cell adhesion molecule-1 (PECAM-1). An upregulation of ICAM, VCAM-1, and
PECAM-1 was seen in veins that had undergone distention when compared with the nondis‐
tended vein [15]. The expression of these cell adhesion molecules is important because an
interaction of VCAM-1 and ICAM-1 with monocytes facilitates the monocytes’ recruitment to
the vein [36]. Additionally, interactions of ICAM-1 and VCAM-1 with PECAM-1 mediate the
process of diapedesis of the monocytes into the vessel wall. These initial cell-mediated events
facilitate recruitment of more inflammatory cytokines to the area of injury caused by the
damage from distention. PECAM-1 is constitutively expressed on all endothelium regardless
of cytokine activation.
Toll-like receptors play a very important role in the signaling pathway of inflammation.
Traditionally, TLR4 costimulates with CD14 in chronic conditions. Interestingly TLR4 has also
been shown to bind directly to lipopolysaccharide without CD14 costimulation, leading to
subsequent NF-kappa B activation. Studies in TLR4-deficient mice have shown that despite
the presence of lipopolysaccharide, these mice do not develop neointima, suggesting that
neointimal hyperplasia is a TLR4-dependent process [15], [37]. TLR4 in cooperation with
interleukin-1 receptor plays a significant role in the formation of neointima. TLR4 signaling
also promotes a proinflammatory phenotype and plays a role in the early response to vascular
injury. Therefore, the upregulation of TLR4 may play a role in the development of graft failure
in terms of neointimal hyperplasia. TLR2 activation with MYD88 leads to cytokine production
through NF-kappa B pathways. Thus, these data suggest that vein graft failure is likely a
multifactorial process that includes neointimal hyperplasia and inflammation. Immediate vein
graft failure is most probably due to inflammatory cytokines whereas late failure (1 year after
CABG) is due to neointimal hyperplasia. However, the common cause of both of these
processes is quite possibly exacerbated by SV pressure distention [15].
8. The future of prevention: from the research bench to the operating room
Much interest in reducing neointimal hyperplasia by blocking gene expression is arising. The
cell cycle of endothelial cells is now better understood and therefore has allowed for genetics
to help play a role in preventing stenosis, thrombosis, and ischemia. If the genetic pathways
that are associated with the above process can be fully identified this may ultimately influence
coronary graft patency. Ex-vivo work has been promising to show that blocking of the cell
cycle via gene therapy has slowed down the atherosclerosis that can lead to graft failure [1].
Repeat coronary vascular procedures will continue to be problematic until an understanding
of the mechanisms of vein graft have been elucidated. Thus far, extensive research has been
done on this topic, but an overall consensus exists that the saphenous vein is a very fragile and
easily injured conduit. Great care must be taken while handling the vein during harvest and
preparation to avoid damage or stress to either the external or internal surface of the vein.
Avoiding supra-physiologic pressure, prolonged distention periods and manipulations which
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result in tissue inflammation and injury should be employed to prevent graft failure. Such
efforts are expected to reduce the morbidity associated with saphenous vein graft disease and
repeat coronary artery bypass interventions.
Figure 1. Scanning electron microscopy photomicrographs of vein tissue following harvest and distention. Saphenous
veins underwent endoscopic harvest during bypass grafting procedures with routine pressure distention to ligate side
branches. Vein distention was performed by attaching a syringe to the most anatomically distal portion of the vein. A
segment of vein was obtained prior to distention and several segments along the length of the vein were harvested
after distention and subjected to scanning electron microscopy. Pictures shown in the figure are (A) non-distended
vein (B) most distal portion of vein from origin of distention (C) mid section of saphenous vein graft (D) vein segment
closest to the syringe. Shown in the pictures are endothelial layer starting to change from a smooth flat surface to a
rounded up rough surface.
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